Massachusetts Nonprofits Are Forging New Ways to Remain Vital, According to Publisher of massnonprofit.org
17 mars 2011 11h29 HE | massnonprofit.org
BROOKLINE, MA--(Marketwire - March 17, 2011) -  Nonprofit organizations in Massachusetts are forging creative responses to a changing operating environment that is characterized by higher demand...
Alliance for the Prudent Use of Antibiotics Lauds FDA for Action on Antimicrobial Drugs in Food-Producing Animals
29 juin 2010 13h23 HE | APUA
BOSTON, MA--(Marketwire - June 29, 2010) -  The Alliance for the Prudent Use of Antibiotics (APUA), the leading, independent global organization dedicated to preserving the power of existing...
HemaQuest Pharmaceuticals Receives European Orphan Medicinal Product Designations for Therapeutic to Treat Hemoglobin Disorders
26 mars 2009 12h54 HE | HemaQuest Pharmaceuticals
BOSTON, MA--(Marketwire - March 26, 2009) - HemaQuest Pharmaceuticals today announced that it has received two orphan medicinal product designations from the European Commission for its product...
HemaQuest Pharmaceuticals Announces Clinical Progress on New Sickle Cell Anemia Drug
09 déc. 2008 12h01 HE | HemaQuest Pharmaceuticals
SAN FRANCISCO, CA--(Marketwire - December 9, 2008) - HemaQuest Pharmaceuticals announced today the successful completion of Phase 1 clinical trials of HQK-1001, an orally-administered therapeutic...
Fashion Accessories First Acquires Catherine Stein Design of New York
13 nov. 2008 10h59 HE | Fashion Accessories First, Inc.
GREENVILLE, RI--(Marketwire - November 13, 2008) - Fashion Accessories First, Inc. (FAF), one of the leading suppliers of fashion jewelry and accessories to retailers worldwide, today announced that...
HemaQuest Pharmaceuticals Receives Orphan Drug Designations for Therapeutic to Treat Hemoglobin Disorders
04 nov. 2008 09h00 HE | HemaQuest Pharmaceuticals
BOSTON, MA--(Marketwire - November 4, 2008) - HemaQuest Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has awarded the company orphan drug designations for sickle...
HemaQuest Announces Initiation of Phase I Clinical Trial of HQK-1001 to Treat Hemoglobin Disorders
17 janv. 2008 09h00 HE | HemaQuest Pharmaceuticals
NEWTON, MA--(Marketwire - January 17, 2008) - HemaQuest Pharmaceuticals, which received its first round of venture financing three months ago, today announced that the U.S. Food and Drug...
HemaQuest Announces $20M Series A Financing for Anemia Drug Development
01 nov. 2007 10h30 HE | HemaQuest Pharmaceuticals
NEWTON, MA--(Marketwire - November 1, 2007) - HemaQuest Pharmaceuticals, a new company developing proprietary small molecule therapeutics to treat serious blood disorders, today announced that it...